Get the Stockscreener App
50.18
2.15%
-1.10
After Hours:
50.12
-0.06
-0.12%
Exact Sciences Corp Stock (EXAS) Latest News
Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™. - GlobeNewswire Inc.
2 Stocks Down 59% and 34% to Buy and Hold - The Globe and Mail
Exact Sciences to Participate in March Investor Conferences - BioSpace
Exact Sciences price target raised to $73 from $70 at Scotiabank - TipRanks
Healthcare Spotlight: Exact Sciences Takes Center Stage at Two Major March Conferences - StockTitan
Exact Sciences Stock Climbs After Strong Q2 Results - MSN
Exact Sciences Reports Strong Revenue Growth in 2024 - TipRanks
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday? - Benzinga
Exact Sciences Corp Earnings Call Highlights Growth - TipRanks
Exact Sciences Earnings: Guidance at the Low End of Our Expectations, but Shares Remain Attractive - Morningstar
Exact Sciences Has an Established Colon Cancer Screening Franchise and a Progressing Pipeline - Morningstar
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts - Benzinga
TD Cowen sees upside in Exact Sciences stock, maintains $86 target - Investing.com
Exact Sciences stock price target cut to $65 at BTIG - Investing.com India
Exact Sciences Corporation (NASDAQ:EXAS) Q4 2024 Earnings Call Transcript - Insider Monkey
Exact Sciences stock price target cut to $65 at BTIG By Investing.com - Investing.com South Africa
Exact Sciences Reports Robust Q4 Earnings, Surpassing Revenue ProjectionsNews and Statistics - IndexBox, Inc.
Exact Sciences (EXAS) PT Lowered to $65 at BTIG - StreetInsider.com
Exact Sciences: Q4 Earnings Snapshot - mySA
Exact Sciences Corp (EXAS) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com
Exact Sciences Corp (EXAS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Exact Sciences 2025 revenue guidance range includes consensus - MSN
Exact Sciences Announces Fourth Quarter 2024 Results - BioSpace
Exact Sciences Corp reports results for the quarter ended December 31Earnings Summary - TradingView
EXACT SCIENCES Earnings Results: $EXAS Reports Quarterly Earnings - Nasdaq
Exact Sciences Corp Plans To Launch Three New Cancer Tests In 2025 -February 19, 2025 at 05:44 pm EST - Marketscreener.com
EXACT SCIENCES CORP SEC 10-K Report - TradingView
Exact Sciences Stock Slides On Q4 Earnings: The Details - Benzinga
Exact Sciences stock falls despite Q4 earnings beat By Investing.com - Investing.com Australia
Exact Sciences stock falls despite Q4 earnings beat - Investing.com
Exact Sciences: Q4 Earnings Snapshot -February 19, 2025 at 04:43 pm EST - Marketscreener.com
Exact Sciences Q4 Net Loss Widens, Revenue Up; Sets Outlook -February 19, 2025 at 04:22 pm EST - Marketscreener.com
EXACT Sciences earnings beat by $0.27, revenue topped estimates - Investing.com
Exact Sciences Corp. Reports Fourth Quarter and Full Year 2024 Results - TradingView
Can Exact Sciences' New Cancer Tests Transform Early Detection? Q4 Revenue Surges 10% - StockTitan
U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy’s Petition Challenging Validity of a Second Patent Asserted by Exact Sciences - Business Wire
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Banque Pictet & Cie SA Has $3.97 Million Stake in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences (EXAS) Projected to Post Earnings on Wednesday - MarketBeat
8,508 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors - MarketBeat
Barclays sets Exact Sciences stock price target at $70 with Overweight rating - MSN
EXACT Sciences is Now Oversold (EXAS) - Nasdaq
abrdn plc Grows Stock Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Reduces Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
EULAV Asset Management Sells 20,000 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Thompson Investment Management Inc. Buys 36,505 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
When Can We Expect A Profit From Exact Sciences Corporation (NASDAQ:EXAS)? - Yahoo Finance
Exact Sciences Co. (NASDAQ:EXAS) Position Cut by Jennison Associates LLC - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Swedbank AB Buys 13,333 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Receives $72.76 Average Price Target from Brokerages - MarketBeat
Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing - BioSpace
1.50%
0.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):